SuperworthCelldex Therapeutics shares outstanding CLDX
Diluted shares outstanding, averaged over each quarter, from 2010.
- Latest quarter, to Jun 30, 2026
- 77.8M
- On a year earlier
- +17.2%
- more shares
Celldex Therapeutics had 77.8M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 17.2% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 66.5M | +0% |
| FY2024 | 66.4M | +28% |
| FY2023 | 52M | +10% |
| FY2022 | 47.1M | +1% |
| FY2021 | 46.7M | +18% |
| FY2020 | 39.6M | +141% |
| FY2019 | 16.4M | +41% |
| FY2018 | 11.6M | +28% |
| FY2017 | 9.1M | +27% |
| FY2016 | 7.2M | +9% |
| FY2015 | 6.6M | +10% |
| FY2014 | 6M | +8% |
| FY2013 | 5.5M | +33% |
| FY2012 | 4.2M | +42% |
| FY2011 | 2.9M | +38% |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 77.8M | +17% | |
| Q1 FY26 | 66.6M | +0% | |
| Q4 FY25 | 66.5M | +0% | |
| Q3 FY25 | 66.4M | +0% | |
| Q2 FY25 | 66.4M | +1% | |
| Q1 FY25 | 66.4M | +13% | |
| Q4 FY24 | 66.4M | +28% | |
| Q3 FY24 | 66.3M | +40% | |
| Q2 FY24 | 66M | +40% | |
| Q1 FY24 | 58.9M | +25% | |
| Q4 FY23 | 52M | +10% | |
| Q3 FY23 | 47.3M | +1% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Celldex Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.